Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
146.93B
Market cap146.93B
Price-Earnings ratio
20.30
Price-Earnings ratio20.30
Dividend yield
6.50%
Dividend yield6.50%
Average volume
41.47M
Average volume41.47M
High today
$26.25
High today$26.25
Low today
$25.76
Low today$25.76
Open price
$26.16
Open price$26.16
Volume
14.88M
Volume14.88M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$21.97
52 Week low$21.97

Stock Snapshot

The current Pfizer(PFE) stock price is $25.78, with a market capitalization of 146.93B. The stock trades at a price-to-earnings (P/E) ratio of 20.30 and offers a dividend yield of 6.5%.

On 2026-05-08, Pfizer(PFE) stock traded between a low of $25.76 and a high of $26.25. Shares are currently priced at $25.78, which is +0.1% above the low and -1.8% below the high.

The Pfizer(PFE)'s current trading volume is 14.88M, compared to an average daily volume of 41.47M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $21.97.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $21.97.

PFE News

Simply Wall St 8h
Assessing Pfizer’s Valuation As Shares Hover Near Recent Levels

Advertisement Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is back in focus after recent trading left the stock around $26.48. This has prompted...

Assessing Pfizer’s Valuation As Shares Hover Near Recent Levels
Nasdaq 21h
Forget Eli Lilly: These 2 Stocks Have More Upside

Key Points Investors have placed a high valuation on Eli Lilly because they believe GLP-1 drugs represent a massive opportunity. Eli Lilly is growing quickly...

Forget Eli Lilly: These 2 Stocks Have More Upside
TipRanks 23h
Pfizer’s Next Lyme Shot: What a Fifth-Dose VLA15 Trial Signals for PFE Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

Analyst ratings

50%

of 30 ratings
Buy
40%
Hold
50%
Sell
10%

More PFE News

TipRanks 23h
Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

Nasdaq 1d
Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics

Key Points Pfizer's cash flow visibility is now greater thanks to legal wins. The company isn't planning a mega-merger that could affect its ability to cover...

Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics
Seeking Alpha 2d
Novavax rises after strong Q1 beat driven by Pfizer deal

Novavax (NVAX) shares added ~6% in the premarket on Wednesday after the COVID-19 vaccine maker well exceeded Street forecasts with its Q1 financials, thanks to...

Novavax rises after strong Q1 beat driven by Pfizer deal
TipRanks 2d
Pfizer Rated Hold as Near-Term COVID Drag Balances Long-Term Growth Outlook; $28 Price Target Reiterated

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer and keeping the price target at $28.00. Unlock hedge fund-level data and powerful...

TipRanks 3d
Pfizer Earnings Call Highlights Growth Beyond COVID

Pfizer Inc ((PFE)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and powerful...

Simply Wall St 3d
Pfizer’s First PROTAC Approval Adds New Dimension To Oncology Story

FDA approves VEPPANU (vepdegestrant), co developed by Arvinas and Pfizer, as the first PROTAC protein degrader therapy for advanced ER+/HER2, ESR1 mutated breas...

Pfizer’s First PROTAC Approval Adds New Dimension To Oncology Story
TipRanks 3d
Pfizer sees high-single-digit annual revenue increases 2029-2033, WSJ reports

Pfizer (PFE) expects to return to consistent growth by 2029, targeting high-single-digit annual revenue increases through 2033, supported by a predictable post-...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.